A new ligand extends the half-life of peptide drugs from minutes to days

Peptides are biological molecules, made up of short sequences of amino acids. Because they are easy to synthesize, show low toxicity and high efficiency, peptides such as insulin and other hormones can be used as drugs. But peptides are quickly cleared by the kidneys, which means that we can only use peptide drugs that act within minutes. This problem can be overcome by connecting peptides to ligands that bind blood-serum proteins such as albumin, allowing the peptide to linger in the bloodstream longer. EPFL scientists have now developed such a ligand, which is easy to synthesize and has a high affinity for human albumin. Published in Nature Communications, the new ligand could potentially extend the half-life of peptides from minutes to several days.

Peptides combine a number of attractive features for drugs: low toxicity and immune reactions, high affinity and efficacy for their targets, and accessible chemical synthesis. The only problem is "renal clearance": peptides are generally cleared by the kidneys within a few minutes of entering the patient's blood. For example, one of the most common peptides, insulin, has a bloodstream half-life of only 4-6 minutes. Another hormone, oxytocin -- given intravenously to induce or accelerate labor -- has a half-life of 10-15 minutes.

Such short timeframes imposed by renal clearance severely limit the therapeutic potential of these potentially ideal drugs. One promising way to increase the half-life of peptides is to "piggy-back" them onto blood-serum proteins, such as albumin, which is the most abundant protein in the blood serum and has a half-life of nineteen days. This however, requires an intermediate ligand molecule that can be attached to the peptide during synthesis, and also have a high affinity and selectivity for human albumin.

The lab of Christian Heinis at EPFL has now developed such a ligand, which has a high affinity for human albumin and -- more importantly -- is easy to synthesize and attach to a peptide. The ligand is made by fusing a fatty acid with another peptide. The resulting molecule is referred to as a "chimera" and combines the best of two worlds from the field of albumin ligands.

Previous efforts built ligands based on either fatty acids or peptides, and have tried them on insulin. But whereas fatty acids somewhat extended the half-life of insulin, they generally didn't bind albumin very strongly. On the other hand, peptide-based ligands bind albumin well, but showed low solubility, meaning it didn't distribute insulin in the blood very well.

The new ligand literarily brings together the advantages of both fatty acids and peptides. The researchers searched for an amino acid sequence that would complement the fatty acid's weak binding of albumin. Using an elegant "iterative" synthesis and screening method they discovered a peptide sequence that increases the binding of the fatty acid twenty-seven times. The final chimera ligand binds human albumin with high affinity (Kd = 39 nM), is highly soluble, and can be appended to peptide drugs using standard synthesizing techniques.

The researchers demonstrated in vivo that the ligand prolongs the half-life of several bioactive peptides more than 25-fold. They then appended the ligand to an actual peptide developed to treat pathogenic thrombosis, which has a notoriously impractical short half-life. The ligand was shown to extend the effectiveness of the peptide by several hours, inhibiting the disease in rabbits.

"We expect that the tag presented in our work will interest a larger research and business audience because it is applicable to virtually any peptide moiety, including small proteins," says Heinis. "The ligand can be appended to any peptide during solid-phase peptide synthesis on standard synthesizers, making it easily accessible for academic and industry labs."

The innovative technology can potentially also be applied to modulate the pharmacokinetic properties of bicyclic peptides developed by Bicyclic Therapeutics, a startup co-founded by Christian Heinis and Sir Greg Winter (MRC LMB Cambridge, UK) in 2009, and of which EPFL is a shareholder. On June 1 this year, Bicycle Therapeutics received a series B investment of 52 million US dollars. The company's focus is the bicyclic peptide (Bicycle®) product platform, which combines properties of several therapeutic entities in a single modality: exhibiting the affinity and selective pharmacology associated with antibodies; the distribution kinetics of small molecules, allowing rapid tumor penetration; and the "tuneable" pharmacokinetic half-life and renal clearance of peptides.

Alessandro Zorzi, Simon J. Middendorp, Jonas Wilbs, Kaycie Deyle, Christian Heinis.
Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides.
Nature Communications 8, 16092. DOI: 10.1038/ncomms16092.

Most Popular Now

Delivering insulin in a pill

Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill. But for millions o...

Can aspirin treat Alzheimer's?

A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological r...

FDA approves first drug comprised of an active ing…

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms o...

Researchers develop a new method for turning skin …

Our bodies consist of many different kinds of cells, each with their own role. The Japanese scientist Shinya Yamanaka had made earlier the discovery, earning the Nobel Pr...

Some existing anti-cancer drugs may act in part by…

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti...

Poliovirus therapy for recurrent glioblastoma has …

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, wit...

Human clinical trial reveals verapamil as an effec…

Researchers at the University of Alabama at Birmingham Comprehensive Diabetes Center have discovered a safe and effective novel therapy to reduce insulin requirements and...

Novartis Clear about Psoriasis survey data highlig…

Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publica...

New small molecules pave the way for treating auto…

The innate immune system is the first line of defense, with cells that quickly identify "foreign" motifs from viruses and bacteria and mount up a counterattack to elimina...

How targeting metabolism can defeat cancer stem ce…

Researchers are the University of Michigan Rogel Cancer are unraveling a crucial thread that explains why cancer so often becomes resistant to treatment. In a breakthroug...

Amgen and MBC Biolabs announce winners of the Amge…

Amgen (NASDAQ:AMGN) and MBC BioLabs (formerly QB3@953) announced that Delve Therapeutics and Mitokinin have won the Amgen Golden Ticket at MBC BioLabs. Each company recei...

FDA warns of imposters sending consumers fake warn…

The U.S. Food and Drug Administration is warning consumers about criminals forging FDA warning letters to target individuals who tried to purchase medicines online or ove...